Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease: Statement
Full statement by bharat Biotech. Says,"second interim results showed India’s First COVID-19 Vaccine had demonstrated strong primary efficacy against severe COVID-19 disease"
You can follow @sidhant.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled: